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experimental rabbit vein grafts
Koichi Morisaki, MD,a Rei Shibata, MD, PhD,b Noriko Takahashi, MD,a Noriyuki Ouchi, MD, PhD,c
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Background: Intimal hyperplasia is a major obstacle to patency after vein grafting. Several clinical trials revealed that
pioglitazone, a peroxisome proliferator-activated receptor- ligand, exerts beneficial actions on cardiovascular complica-
tions. We investigated whether pioglitazone modulates intimal hyperplasia in experimental rabbit autologous vein grafts.
Methods: Male Japanese White rabbits were randomly divided into two groups: one group received pioglitazone as food
admixture at a concentration of 0.01%, and the other did not (control). One week later, each group underwent reversed
autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone
therapy was continued after surgery and until harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days. Two
weeks after implantation, proliferative cells in the neointima were identified by immunohistochemical staining with Ki-67
monoclonal antibody. To determine apoptotic cells, we performed terminal deoxynucleotidyl transferase-mediated
deoxyuride-5=-triphosphate nick-end labeling (TUNEL) staining. Blood samples were collected at 28 days after
implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were
determined by Western blot analysis. Finally, we assessed adiponectin-related signaling pathway, 5= adenosine mono-
phosphate-activated protein kinase (AMPK), and extracellular signal-regulated kinase (ERK) in the grafted vein by
Western blot analysis.
Results: Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular
vein grafts in the pioglitazone group (0.54  0.04 mm2) vs control (0.93  0.04 mm2; n  7; P < .01). Pioglitazone
treatment reduced the number of Ki-67-positive proliferating cells in the neointima of the vein grafts at 14 days after
implantation in the pioglitazone group (4.1%  1.1%) vs the controls (16.8%  1.7%; P < .05). The frequency of
TUNEL-positive apoptotic cells was enhanced by pioglitazone (3.5%  0.5%) vs the controls (1.2%  0.1%; P < .05).
Pioglitazone treatment also increased plasma levels of adiponectin, a vascular protective hormone, and led to an increase
in phosphorylation of AMPK and a decrease in phosphorylation of ERK in the grafted vein.
Conclusions: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to
suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of
graft failure after bypass grafting. (J Vasc Surg 2011;54:1753-9.)
Clinical Relevance: Intimal hyperplasia is a major obstacle to patency after vein grafting. Various treatments to reduce
neointimal hyperplasia have been examined; however, a standard clinical treatment has not yet been established. We
report that pioglitazone, a peroxisome proliferator-activated receptor- ligand, inhibits intimal hyperplasia of autologous
vein grafts. Pioglitazone also increased adiponectin, an adipose-derived hormone. Obesity-related complications, such as
diabetes, are closely associated with autologous vein graft stenosis after bypass surgery. The findings reported here
suggest that pharmacologic approaches aimed at increasing adiponectin production, such as pioglitazone, can contribute
to the prevention of autologous vein graft stenosis in obese individuals.
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nAutologous vein graft is the most common and suitable
conduit for the reconstruction of arterial occlusive disease
such as coronary artery disease (CAD) and peripheral arte-
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doi:10.1016/j.jvs.2011.06.081ial disease.1 However, only 50% to 80% of autologous vein
rafts remain patent at 5 to 10 years. Intimal hyperplasia of
rterialized vein after bypass surgery is an important cause
f late graft failure.2,3 Thus, it is necessary to develop a
romising adjunctive therapy for the prevention of intimal
yperplasia in patients with bypass graft surgery.
Pioglitazone, a peroxisome proliferator-activated
eceptor- (PPAR) ligand, is widely used for the treat-
ent of type 2 diabetes.4 The clinical trials in the Prospec-
ive Pioglitazone Clinical Trial in Macrovascular Events
tudy demonstrated that pioglitazone improved cardiovas-
ular outcome in patients with type 2 diabetes.5 A recent
eta-analysis revealed beneficial effects of pioglitazone on
ardiovascular disease.6 Of note, in patients with nondia-
etic CAD, 6-month treatment with pioglitazone reduced
eointima volume after coronary stent implantation in a
andomized, placebo-controlled, double-blind trial.7
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December 20111754 Morisaki et alConsistent with these clinical observations, a number
of experimental studies show that pioglitazone attenuates
neointimal thickening in response to vascular injury8-10 and
suppresses growth factor-stimulated proliferation and mi-
gration of vascular smoothmuscle cells (SMCs).11,12 These
findings indicate that in addition to its glucose-lowering
effect, pioglitazone acts as a biologically relevant modulator
of vascular remodeling. We investigated the effect of the
systemic administration of pioglitazone on autologous vein
grafts using an experimental rabbit vein graft model.
MATERIALS AND METHODS
Antibodies to 5= adenosine monophosphate-activated
protein kinase (AMPK) 1, phosphorylated AMPK 1, and
phosphorylated extracellular signal-regulated kinase (ERK)
were purchased from Santa Cruz Biotechnology (Santa
Cruz, Calif). Total ERK antibody was purchased from Cell
Signaling (Beverly, Mass). Adiponectin antibody for de-
tecting all forms of adiponectin was purchased from R&D
Systems (Minneapolis, Minn). Pioglitazone was a gift from
Takeda Pharmaceutical Company Limited (Tokyo, Japan).
Experimental protocol. The study protocol was ap-
proved by the Institutional Animal Care and Use Commit-
tee of Nagoya University School of Medicine. The study
also conformed with the requirements in Guiding Princi-
ples for the Care and Use of Laboratory Animals (National
Institutes ofHealth publication 80-23, revised 1985).Male
JapaneseWhite rabbits (2.5-3.0 kg) were randomly divided
into two groups: one group was treated with pioglitazone,
and one group was not (controls). Treatment with piogli-
tazone was initiated 1 week before surgery and continued
for 4 weeks as a food admixture (3 mg/kg/d), consistent
with previous reports.13,14
Vein graft implantation. Rabbits underwent re-
versed autologous vein bypass grafting of the right com-
mon carotid artery using the external jugular vein, as de-
scribed previously.15-17 In brief, anesthesia was induced
intramuscularly with ketamine hydrochloride (50 mg/kg)
and xylazine (10 mg/kg) and maintained with intravenous
administration of ketamine hydrochloride (10 mg/kg) and
xylazine (10 mg/kg).
The right jugular vein and the right common carotid
artery were exposed, and the branches of the jugular vein
were ligated. Approximately 2 cm of the vein was taken for
autologous reversed vein graft. The harvested graft was
kept moist in heparinized saline (5 IU/mL) at room tem-
perature. Rabbits were systemically heparinized (200 IU/
kg), and the right common carotid artery was clamped at
the proximal and distal ends. The vein graft was anasto-
mosed in an end-to-end fashion into the divided artery with
interrupted 8-0 polypropylene suture under a surgical mi-
croscope.
Harvest of implanted vein grafts. The autologous
vein grafts were harvested under general anesthesia 4 weeks
after being implanted. In brief, the graft was isolated and
harvested after systemic heparinization (200 IU/kg intra-
venously), and the rabbits were euthanized by an intrave-
nous overdose of pentobarbital (50 mg/kg). tThe harvested graft was fixed 4% formaldehyde at 100
m Hg for 30 minutes. The perfused vein graft was im-
ersed in the same fixative overnight at room temperature.
our sections were obtained from each vein graft. Each
ample was embedded in paraffin and cut into 5-m sec-
ions.
Assessment of intimal hyperplasia. Intimal hyper-
lasia was assessed in the harvested vein grafts in each group
n  7, respectively). Four sections were obtained from
ach vein graft and processed as described in the previous
ection. Each section was deparaffinized in a xylene/etha-
ol series and stained with hematoxylin and eosin or with
lastica van Gieson. The intimal area, medial area, and total
umen area were measured by MACSCOPE (Mitani Co,
ukui, Japan) for each section. The average of the four
ections was considered to represent the intimal hyperplasia
f the vein graft. These values were used for statistical
nalysis.
Immunohistochemical staining. Vein grafts (n  4,
n each group) were harvested 14 days after implantation,
rocessed as described previously, and then deparaffinized
n a xylene/ethanol series. Proliferative cells in the neoin-
ima were identified by immunohistochemical staining with
i-67 monoclonal antibody (DAKO Cytomation Inc, Car-
enteria, Calif). To determine apoptotic cells, we also per-
ormed terminal deoxynucleotidyl transferase-mediated
eoxyuride-5=-triphosphate nick-end labeling (TUNEL)
taining (Roche, Mannheim, Germany), as previously
escribed.16,17 The total, Ki-67-positive, and TUNEL-
ositive nucleated cells in the neointima were counted
original magnification of 400) by three observers who
ere blinded to the groups. The values obtained by the
hree observers were averaged in each section. The quanti-
ative analysis was performed in eight independent sections
n each rabbit. The number of Ki-67-positive and TUNEL-
ositive cells/total number of cells counted was defined as
he Ki-67 index and TUNEL index of the vein graft.
Western blot analysis. The grafted vein samples ob-
ained at 14 days after implantation were excised and
ashed with ice-cold phosphate-buffered saline, cut into
-mm-wide strips, and immediately frozen in dry ice/
cetone. Frozen strips were homogenized in ice-cold lysis
uffer containing 20mM Tris-HCl (hydrochloride) (pH
.0), 1% NP-40, 150mM NaCl, 0.5% deoxycholic acid,
mM sodium orthovanadate, and protease inhibitor cock-
ail (Sigma, St. Louis, Mo). Identical amounts of protein
ere separated with denaturing sodium dodecylsulfate 10%
olyacrylamide gels. The membranes were immunoblotted
ith the primary antibodies at a 1:1000 dilution, followed
y secondary antibody at a 1:5000 dilution. Bands were
isualized using an enhanced chemiluminescence Western
lotting Detection Kit (Amersham Pharmacia Biotech,
iscataway, NJ). Western blot analysis was examined
mong control, treatment, and sham-operated rabbits.
Measurement of metabolic parameters. Blood sam-
les were collected from rabbits after an overnight fast at 28
ays after implantation. Plasma glucose, total cholesterol,
riglyceride, and low-density and high-density lipoprotein
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Volume 54, Number 6 Morisaki et al 1755cholesterol levels weremeasured with enzymatic kits (Wako
Chemicals, Shiga, Japan). Adiponectin levels were deter-
mined by Western blot analysis. After centrifugation, the
supernatant (0.7 L) was diluted into nonreducing sample
buffer and separated with denaturing sodium dodecylsul-
fate 10% polyacrylamide gels, as described previously.18
Sample size calculation and statistical analysis. We
assumed a mean difference of 30 m with a standard
deviation of 10 m, referring to a previous report.16 The
study was designed with 5% level of significance (  0.05)
and 90% power to reject the null hypothesis of equivalence
between the two treatment groups. To achieve this objec-
tive, five rabbits were required for each group. Considering
that some of the grafted veins would be occluded, we
examined intimal hyperplasia of grafted veins of seven in
each group. StatView 5.0 software (SAS Institute, Cary,
NC) was used for statistical calculations. Data are presented
as means standard error of the mean. All of the data were
subjected to one-way analysis of variance (ANOVA), fol-
lowed by Scheffé analysis for comparison between any two
means. Statistical significance was also evaluated using
ANOVA for comparison among the three groups (control,
treatment, and sham operation groups). A value of P .05
was considered significant.
RESULTS
Effect of pioglitazone on intimal hyperplasia of the
vein graft. All rabbits survived the implantation procedure
and appeared healthy during the follow-up period. All of
the vein grafts were patent at harvest. Pioglitazone treat-
ment had no effects on heart rate, blood pressure, or body
weight during the observation period. There were no sta-
tistically significant differences between rabbits treated with
pioglitazone for 28 days and the controls in levels of plasma
glucose, total cholesterol, triglycerides, and low-density
and high-density lipoprotein cholesterol (Table I).
To assess the effect of pioglitazone on intimal hyper-
plasia of vein grafts, rabbits underwent reversed autologous
vein graft surgery with the external jugular vein into the
common carotid artery. Intimal hyperplasia developed in
the grafted vein at 4 weeks after implantation in both
Table I. Metabolic parameters in rabbits treated with
and without pioglitazonea
Variableb
Control
(mg/dL)
Pioglitazone
(mg/dL) P
Plasmas glucose 214  19 196  19 .50
Triglyceride 37.4  6.3 24.9  4.3 .13
Cholesterol
Total 26.0  3.7 30.4  3.5 .40
LDL 5.9  1.2 6.9  1.7 .64
HDL 14.6  2.2 20.3  2.3 .09
LDL, Low-density lipoprotein; HDL, high-density lipoprotein.
aBlood samples were collected from rabbits treated with or without piogli-
tazone (control) for 28 days after surgery.
bData are shown as mean  standard error of the mean.groups (n  7, respectively; Fig 1). The degree of intima srea in the pioglitazone-treated rabbits at 2 and 4 weeks
fter implantation was markedly suppressed compared with
he untreated controls (P  .01; Table II). The intima/
edia index at 2 and 4 weeks after implantation was also
ignificantly smaller in the pioglitazone-treated rabbits than
n the untreated rabbits (P  .01) (Table II). The differ-
nces in medial area and total lumen area were not signifi-
ant (Table II).
Effect of pioglitazone on cell proliferation and ap-
ptosis in the vein graft. We next assessed the effect of
ioglitazone on cell proliferation and apoptosis at day 14
fter implantation, because maximum numbers of Ki-67-
ositive proliferating or TUNEL-positive apoptotic cells
ere observed.16,17 In the neointimal lesions, pioglitazone
reatment significantly reduced the frequency of Ki-67-
ositive cells by 53% compared with nontreatment (Fig 2).
n contrast, pioglitazone treatment increased the number
f TUNEL-positive cells in the neointimal lesions by a
actor of 2.2 compared with nontreatment (Fig 3).
Effect of pioglitazone on circulating adiponectin
evels. Plasma adiponectin levels in each group were as-
essed by Western blot analysis. The vein graft surgery did
ot affect adiponectin protein levels in the plasma. Treat-
ent with pioglitazone resulted in a 1.8-fold increase in the
lasma adiponectin level independent of the vein graft
ig 1. Effect of pioglitazone on the development of intimal hy-
erplasia of the vein graft at 28 days after implantation. A, Repre-
entative photomicrographs of the middle portion of the autolo-
ous vein grafts from rabbits treated with or without pioglitazone
elastica van Gieson stain; original magnification40). The arrow-
eads indicate the internal elastic lamina. B, The arrowheads indi-
ate the internal elastic lamina (elastica van Gieson statin; original
agnification 200).urgery (Fig 4).
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December 20111756 Morisaki et alEffects of pioglitazone on AMPK and ERK activi-
ties in the vein graft. Phosphorylation of AMPK and ERK
in the grafted vein was assessed by Western blot analysis
because adiponectin modulates vascular remodeling by di-
rectly affecting these signaling pathways in vascular cells.
The level of AMPK phosphorylation in the grafted vein was
significantly higher than that in sham-operated jugular
vein. The magnitude of this induction was greater in the
pioglitazone-treated rabbits than in the untreated rabbits
(Fig 5,A). The phosphorylation of ERK in the grafted vein
was markedly increased by the vein graft surgery, but this
induction was significantly less in the pioglitazone-treated
rabbits than in the untreated rabbits (Fig 5, B).
DISCUSSION
The present study provides evidence that pioglitazone
can suppress the intimal hyperplasia of vein grafts implanted
in the arterial circulation. Treatment of rabbits with piogli-
tazone attenuated intimal thickening of carotid interposi-
tion-reversed jugular vein grafts through suppression of cell
proliferation and induction of apoptosis.
A major process that leads to neointima formation in
Table II. Morphometric analysisa
Variableb
Day 14
Control
(n  4)
Pioglitazone
(n  4)
Intima area, mm2 0.66  0.04 0.46  0.02
Media area, mm2 0.91  0.05 0.99  0.04
Lumen area, mm2 11.5  0.65 12.36  0.67
Intima/media index 0.730  0.002 0.459  0.001
aThe degree of intima area in the pioglitazone-treated rabbits at 2 and 4 we
rabbits (P  .01). The intima/media index at 2 and 4 weeks after implanta
untreated rabbits (P  .01). There were no significant differences in medial
bData are shown as mean  standard error of the mean.
Fig 2. Effect of pioglitazone on smooth muscle cell pro
implantation. A, Representative photomicrographs with
grafts from rabbits treated with or without pioglitazo
Ki-67-positive cells in the neointima. B, Graph shows Ki
with or without (control) pioglitazone (n  4 in each gr
error of the mean.arterialized vein grafts is the SMC accumulation in the aeointima, which is the sum of cell migration, cell prolifer-
tion, and apoptotic cell loss.19-21 In our experimental
abbit vein graft model, SMC replication and apoptosis
ere transiently and coincidentally observed after implan-
ation in the neointima with a peak at day 14, declining to
ower levels at day 28, consistent with previous studies.16,17
reatment with pioglitazone significantly decreased cell
roliferation and increased apoptosis in the neointima at
ay 14 after implantation. Accordingly, inhibition of neo-
ntima formation by pioglitazone appears to be attributable
o suppression of SMC proliferation and induction of SMC
poptosis.
The beneficial actions of pioglitazone on vascular re-
odeling are likely to be at least partly due to its ability to
ctivate AMPK signaling. Activation of AMPK was re-
orted to attenuate angiotensin II-stimulated ERK phos-
horylation and growth of SMCs.22,23 The AMPK activa-
or, 5-aminoimidazole-4-carboxamide ribonucleoside, also
uppressed neointimal formation in a wire injury model of
he rat femoral artery when administered by subcutaneous
njection for 14 days.22 In the present study, pioglitazone
reatment promoted AMPK activation and attenuated ERK
Day 28
P
Control
(n  7)
Pioglitazone
(n  7) P
.01 0.93  0.04 0.54  0.04 .01
.88 0.80  0.03 0.82  0.07 .60
.79 11.5  0.65 11.9  0.67 .77
.01 1.158  0.001 0.652  0.001 .01
er implantation was markedly suppressed compared with untreated control
as also significantly smaller in the pioglitazone-treated rabbits than in the
nd total lumen area.
ion in the vein graft neointima is shown at 14 days after
7 staining of the middle portion of the autologous vein
original magnification 400). The arrowheads show
dex of the neointima in vein grafts from rabbits treated
*P  .05 vs control. The range bars show the standardeks aft
tion wliferat
Ki-6
ne (
-67 in
oup).ctivity in the grafted vein after implantation.
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Volume 54, Number 6 Morisaki et al 1757Pioglitazone increased the expression and secretion of
adiponectin by its ability to activate PPAR in adi-
pocytes.24,25 Adiponectin is downregulated in obesity-
linked diseases, including ischemic heart disease and pe-
ripheral arterial disease.26,27 Adiponectin exerts protective
Fig 3. Effect of pioglitazone on smooth muscle cell ap
implantation. A, Representative photomicrographs with
5=-triphosphate nick-end labeling (TUNEL) staining of
treated with or without pioglitazone (original magnificati
neointima. B, The TUNEL index of the neointima in vei
pioglitazone (n  4 in each group). *P  .05 vs control
Fig 4. Effect of pioglitazone on circulating adiponectin plasma
levels in rabbits treated with or without pioglitazone assessed by
Western blot analysis. A, Representative immunoblot for adi-
ponectin at 28 days after sham operation or implantation. B,
Quantitative analysis of relative changes in adiponectin levels on
day 28 after sham operation or vein graft implantation in rabbits
receiving pioglitazone (Pio) or untreated controls (Co). Adiponec-
tin levels expressed as percentage of the signal intensity of sham-
operated rabbits (n  3 in each group). *P  .05 vs the control
group. The range bars show the standard error of the mean.actions on a variety of metabolic and cardiovascular disor- aers, including insulin resistance,28 atherosclerosis,29,30
ascular dysfunction,31 angiogenesis,32 and cardiac injury,
artly through activating AMPK signaling in target
ells.33,34 We and other groups have recently shown that
he protective effects of pioglitazone on cardiovascular
ystems largely depend on its ability to increase adiponectin
roduction.14 In addition, pioglitazone treatment led to
ncreased AMPK activation and reduced ERK phosphory-
ation in the heart, which largely depend on its ability to
nhance adiponectin levels.14 Lack of adiponectin causes
ncreased intimal hyperplasia in response to vascular injury
n mice.30 Conversely, overexpression of adiponectin re-
uces atherosclerotic lesions in a mouse model of athero-
clerosis.29
We observed here that pioglitazone significantly in-
reased circulating adiponectin levels in rabbits and also
ttenuated ERK activation and stimulated AMPK phos-
horylation in the grafted vein. These data suggest that the
nhibition of neointima formation by pioglitazone is attrib-
ted to modulation of ERK and AMPK signaling pathways
y adiponectin. However, further detailed biochemical and
enetic studies are required to clarify the cause and conse-
uence relation between the upregulation of adiponectin
y pioglitazone and the prevention of autologous vein graft
tenosis.
Obesity-related complications are closely associated
ith autologous vein graft stenosis after bypass sur-
ery.35,36 The findings reported here suggest that elevated
diponectin can contribute to the prevention of the autol-
gous vein graft stenosis in obese individuals. Pharmaco-
ogic approaches aimed at increasing adiponectin produc-
ion, such as pioglitazone treatment, could be useful for
revention of late graft failure after bypass grafting.
The oral administration of pioglitazone caused no
dverse effects in this study. Pioglitazone is widely used
is in the vein graft neointima is shown at 14 days after
inal deoxynucleotidyl transferase-mediated deoxyuride-
iddle portion of the autologous vein grafts from rabbits
400). The arrowheads show TUNEL-positive cells in the
fts is shown for rabbits treated with or without (control)
range bars show the standard error of the mean.optos
term
the m
on
n gras an insulin sensitizer in the treatment of type 2 diabetes
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December 20111758 Morisaki et almellitus. Therefore, we believe the use of pioglitazone as
a therapeutic approach could be safe and beneficial for
the treatment of cardiovascular disease in humans.
The present study has several limitations. First, we did
not measure PPAR activities and pioglitazone concentra-
tions. In the present study, rabbits were fed an average of
80 grams of food per day; therefore, the daily dosage of
pioglitazone was about 3 mg/kg/d. This dose was deter-
mined from the recent report by Shiomi et al37 demonstrat-
ing that the dose of pioglitazone for treatment of mice and
rabbits is 3 mg/kg, which is similar to the dosage of oral
administration in humans. Under these conditions, we
confirmed the effect of pioglitazone on messenger RNA
levels of PPAR-regulated genes, aP2 in the grafted vein, by
using real-time polymerase chain reaction. Pioglitazone
upregulated aP2 transcript levels in the grafted vein com-
pared with controls (data not shown). A recent report
indicated that the genetic ablation of adiponectin did not
affect the pioglitazone-induced expression of other PPAR-
responsive genes, including aP2, in various tissue.38 Col-
lectively, pioglitazone might exert both direct and indirect
actions on the grafted vein.
Second, we did not assess the effect of pioglitazone
on re-endothelialization after bypass grafting. Treatment
with pioglitazone was reported to accelerate re-endothe-
lialization after vascular injury in rabbits.39 Thus, piogli-
tazone might affect endothelial cells after autologous
Fig 5. Effects of pioglitazone on 5= adenosine monop
signal-regulated kinase (ERK) activities of the vein gra
AMPK in the vein grafts from rabbits treated with or
implantation. B, Phosphorylation (P-) of ERK in the ve
controls (Co) at 14 days after sham operation or implant
protein and expressed as percentage of the signal intensi
vs the control group. The range bars show the standardbypass grafting.ONCLUSIONS
Our present study clearly demonstrates that the long-
erm administration of pioglitazone induces suppression of
ntimal hyperplasia development in experimental autolo-
ous vein grafts by its ability to suppress cell proliferation
nd enhance apoptosis. This novel findingmay facilitate the
linical use of PPAR agonists, such as pioglitazone, in
ostoperative patients to prevent late graft failure after
ypass grafting.
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